ULTRAGENYX PHARMACEUTICAL INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.70 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-18
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.70M shares, a 127.40% increase from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 747.57K shares, a 16.86% decline from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 899.12K shares, a 52.93% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 587.92K shares, a 74.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|
| 2025-12-31 | 1.70M shares 10-K · filed 2026-02-18 |
| 2024-12-31 | 747.57K shares 10-K · filed 2025-02-19 |
| 2023-12-31 | 899.12K shares 10-K · filed 2024-02-21 |
| 2022-12-31 | 587.92K shares 10-K · filed 2023-02-17 |
| 2021-12-31 | 336.38K shares 10-K · filed 2022-02-15 |
| 2020-12-31 | 452.08K shares 10-K · filed 2022-02-15 |
| 2019-12-31 | 766.46K shares 10-K · filed 2022-02-15 |
| 2018-12-31 | 812.47K shares 10-K · filed 2021-02-12 |
| 2017-12-31 | 520.35K shares 10-K · filed 2020-02-14 |
| 2016-12-31 | 407.56K shares 10-K · filed 2019-02-20 |
| 2015-12-31 | 130.04K shares 10-K · filed 2018-02-21 |
| 2014-12-31 | 116.87K shares 10-K · filed 2017-02-17 |
| 2013-12-31 | 252.51K shares 10-K · filed 2016-02-26 |
| 2012-12-31 | 9.58K shares 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |